Scios Inc.

Scios Inc. is a biopharmaceutical company whose goal is to discover, develop and commercialize novel human therapeutics for the treatment of cardiorenal and inflammatory disorders and Alzheimer's Disease.
The Company's lead product for the treatment of acute congestive heart failure, Natrecor, recently completed enrollment in a Phase III clinical trial. Results from this trial will be presented at the American Heart Association Scientific Session in November. Scios plans to submit the data from this trial in the form of an amended New Drug Application to the FDA by the end of 2000.
The Company operates a psychiatric sales and marketing division which provides operating cash for research and development efforts.

Activity:

- Manufacturing
- Market Research & Marketing
- Research & Development
- Sales & Distribution

Product / Technology type(s) covered:

- Bio
- Pharmaceuticals / Therapeutics

Therapeutic targets:

- Alzheimer's Disease
- Cardiovascular
- Infectious Diseases

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: